Trial Profile
Effect of changes in skeletal muscle mass (SMM) during first-line sunitinib therapy on oncological outcomes in metastatic renal cell carcinoma (mRCC).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 25 Oct 2018 New trial record
- 16 Oct 2018 Results published in the Targeted Oncology